FCGR3A and cancer: A novel therapeutic modality, the innate cell engager, has been developed to bind simultaneously to NK cells or macrophages via a distinct epitope on CD16A recognized by the CD16A-specific antibody variable domains, and to cancer cells via variable antibody domains specific to cancer epitopes in order to potentiate the NK cell- or macrophage-dependent destruction of cancer cells in solid tumors (209).